Analysts Issue Forecasts for GANX Q1 Earnings

Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - Analysts at Roth Capital issued their Q1 2026 earnings estimates for shares of Gain Therapeutics in a report issued on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan expects that the company will post earnings per share of ($0.27) for the quarter. The consensus estimate for Gain Therapeutics' current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics' Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.27) EPS and Q4 2026 earnings at ($0.30) EPS.

A number of other equities research analysts have also issued reports on GANX. Scotiabank began coverage on shares of Gain Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $12.00 price target on the stock. Chardan Capital reissued a "buy" rating and set a $6.00 target price on shares of Gain Therapeutics in a research note on Friday, March 28th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price on shares of Gain Therapeutics in a research report on Monday, March 17th. Finally, Roth Mkm reissued a "buy" rating and set a $7.00 price target on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $8.20.

Gain Therapeutics Trading Down 7.8 %

GANX stock traded down $0.14 during mid-day trading on Tuesday, reaching $1.65. 454,753 shares of the stock traded hands, compared to its average volume of 285,500. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $3.65. The stock's fifty day moving average is $2.18 and its 200-day moving average is $2.07. The company has a market cap of $45.85 million, a P/E ratio of -1.50 and a beta of 0.18. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07.

Institutional Trading of Gain Therapeutics

A number of institutional investors have recently bought and sold shares of GANX. Geode Capital Management LLC raised its stake in shares of Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company's stock worth $484,000 after purchasing an additional 88,236 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in Gain Therapeutics by 83.6% in the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company's stock worth $212,000 after buying an additional 44,750 shares during the last quarter. Marshall Wace LLP bought a new position in Gain Therapeutics during the fourth quarter valued at approximately $198,000. Northern Trust Corp lifted its stake in Gain Therapeutics by 88.2% in the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after acquiring an additional 39,642 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in Gain Therapeutics in the fourth quarter worth approximately $65,000. Institutional investors and hedge funds own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.